Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-05-16
2006-05-16
Nguyen, Dave Trong (Department: 1633)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S004000, C435S320100, C514S04400A, C424S093100, C536S023100, C536S023530
Reexamination Certificate
active
07045306
ABSTRACT:
The invention relates to methods and products for deregulating gene transcription in neurodegenerative disease associated with an expanded polyglutamine tract in mutant proteins. The invention is useful for preventing and treating diseases associated with expanded polyglutamine tracts, including Huntington's disease. The methods and compositions of the invention are also useful for identifying additional pharmaceutical agents for preventing and treating diseases associated with expanded polyglutamine tracts.
REFERENCES:
patent: 2002/0137663 (2002-09-01), Forman et al.
Dunah, et al. (2002) Science, 296: 2238-43.
Freiman, et al. (2002) Science, 296: 2149-50.
Garret, et al. (1995) Biochemistry, Published by Saunders College Publishing, pp. 970-975.
Langer (2003) Scientific American, 288(4): pp. 50-57.
Albright, S.R. et al., TAFs revisited: more data reveal new twists and confirm old ideas. Gene, 242:1-13, 2000.
Augood, S.J. et al., Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol., 42: 215-221, 1997.
Chiang, C.M. et al., Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators. Science, 267: 531-536, 1995.
Cooper, J.K., et al., Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet., 7: 783-790, 1998.
Dikstein, R. et al., Human TAFII 105 is a cell type-specific TFIID subunit related to hTAFII130. Cell, 87: 137-146, 1996.
Dunah, A.W. et al., Subunit composition of N-methyl-D-aspartate receptors in the central nervous system that contain the NR2D subunit. Mol. Pharmacol., 53: 429-437, 1998.
Furukawa, T. et al., Assembly of partial TFIID complexes in mammalian cells reveals distinct activities associated with Individual TATA box-binding protein-associated factors. J. Biol. Chem., 275: 29847-29856, 2000.
Gangloff, Y.G. et al., The human TFIID components TAF(II)135 and TAF(II)20 and the yeast SAGA components ADA1 and TAF(II)68 heterodimerize to form histone-like pairs. Mol. Cell Biol., 20: 340-351, 2000.
Gutekunst, C.A., et al., Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci., 19: 2522-2534, 1999.
Huang, C.C. et al., Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somatic Cell Mol. Genet., 24: 217-233, 1998.
Hughes, R.E. et al., Therapeutic opportunities in polyglutamine disease. Nature Medicine, 7: 419-423, 2001.
Kazantsev, A. et al., Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci USA, 96: 11404-11409, 1999.
Kegel, K.B. et al., Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding ptotein, and represses transcription. J. Biol. Chem., 277: 7466-7476, 2002.
Krainc, D. et al., Synergistic activation of the N-methyl-D-aspartate receptor subunit 1 promoter by myocyte enhancer factor 2C and Sp 1. J. Biol. Chem., 273: 26218-26224, 1998.
Lahiri, D.K. Electrophoretic mobility shift assay for the detection of specific DNA-protein complex in nuclear extracts from the cultured cells and frozen autopsy human brain tissue. Brain Res. Protoc., 5: 257-265, 2000.
Li, H. et al., Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nature Genet., 25: 385-389, 2000.
Li, S.H. et al., Interaction of Huntington disease protein with transcriptional activator Sp 1. Mol. Cell Biol., 22: 1277-1287, 2002.
Li, S.H. et al., Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum. Mol. Genet., 7: 777-782, 1998.
Luthi-Carter, R. et al., Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Gen., 9: 1259-1271, 2000.
Luthi-Carter, R. et al., Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Gen., 11:1911-1926, 2002.
Mangiarini, L. et al., Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87: 493-506, 1996.
Martindale, D. et al., Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nature Genet., 18: 150-154, 1998.
Mende-Mueller, L.M. et al., Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-Terminal htt fragments in Huntington's disease striatum. J. Neurosci., 21: 1830-1837 2001.
Metsis, M. et al., Cell-type-specific expression of the TFIID component TAF(II)135 in the nervous system. Exp. Cell Res., 269: 214-221, 2001.
Nucifora, F.C. et al., Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291: 2423-2428, 2001.
Paulson, H.L., Toward an understanding of polyglutamine neurodegeneration. Brain Pathology, 10: 293-299, 2000.
Saluja, D. et al., Distinct subdomains of human TAFII130 are required for interactions with glutamine-rich transcriptional activators. Mol. Cell. Biol., 18: 5734-5743, 1998.
Saudou, F. et al., Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 95: 55-66, 1998.
Shimohata, T. et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet., 26: 29-36, 2000.
Steffan, J.S. et al., Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 413: 739-743, 2001.
Steffan, J.S. et al., The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci USA, 97: 6763-6768, 2000.
Surmeier, D.J. et al., Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci., 16: 6579-6591, 1996.
Vonsattel, J.P. et al., Neuropathological classification of Huntington's disease. Neuropathol. Exp. Neurol., 44: 559-577, 1985.
Weeks, R.A. et al., Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol., 40: 49-54, 1996.
Yajima, S. et al., Sp family transcription factors regulate expression of rat D2 dopamine receptor gene. DNA Cell Biol., 17: 471-479, 1998.
Kelly Robert M.
Nguyen Dave Trong
The General Hospital Corporation
Wolf Greenfield & Sacks P.C.
LandOfFree
Method for identifying compounds in vitro that modulate the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for identifying compounds in vitro that modulate the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying compounds in vitro that modulate the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3649417